Price T Rowe Associates Inc Bluebird Bio, Inc. Transaction History

Price T Rowe Associates Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.47 - $1.35 $4,094 - $11,759	8,711 Added 15.92%	63,425 $33,000
Q1 2024 May 15, 2024	BUY	$0.91 - $1.75 $26,492 - $50,947	29,113 Added 113.72%	54,714 $71,000
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $3,175 - $11,620	2,406 Added 10.37%	25,601 $36,000
Q3 2023 Nov 14, 2023	SELL	$3.02 - $4.05 $60,756 - $81,477	-20,118 Reduced 46.45%	23,195 $71,000
Q2 2023 Aug 14, 2023	BUY	$2.79 - $5.03 $25,734 - $46,396	9,224 Added 27.06%	43,313 $143,000
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $15,511 - $40,606	4,940 Added 16.95%	34,089 $109,000
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $5,366 - $7,895	930 Added 3.3%	29,149 $202,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $26,355 - $51,936	7,028 Added 33.17%	28,219 $179,000
Q2 2022 Aug 15, 2022	BUY	$2.94 - $5.23 $1,490 - $2,651	507 Added 2.45%	21,191 $88,000
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $6,121 - $15,942	1,504 Added 7.84%	20,684 $100,000
Q4 2021 Feb 14, 2022	SELL	$8.96 - $16.31 $81,303 - $147,996	-9,074 Reduced 32.12%	19,180 $192,000
Q3 2021 Nov 15, 2021	BUY	$11.24 - $21.0 $663 - $1,239	59 Added 0.21%	28,254 $540,000
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $16.7 Million - $20.4 Million	-923,645 Reduced 97.04%	28,195 $902,000
Q1 2021 May 17, 2021	SELL	$16.59 - $33.89 $1.36 Million - $2.78 Million	-81,980 Reduced 7.93%	951,840 $28.7 Million
Q4 2020 Feb 16, 2021	BUY	$27.5 - $37.92 $28.4 Million - $39.2 Million	1,033,820 New	1,033,820 $44.7 Million

20.2M

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $385M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.